Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 224

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 224
---
 pricing model to determine the fair value of share options granted during the period:

|                          |     |          2024 |     |    2023 |
| Expected dividend yield  |     |             - |     |       - |
| Risk-free interest rate  |     | 2.95% - 4.24% |     |   4.24% |
| Expected term (in years) |     |       5 years |     | 5 years |
| Expected volatility      |     |    95% - 100% |     |  93.10% |

The expected volatility is based on the share price volatility observed for comparable publicly traded companies over a period similar to the life of the options. The expected option life represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government bonds with a remaining term equal to the expected life of the options.

F-19 Medicus Pharma Ltd.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2024 and 2023
[expressed in United States dollars, except share amounts]

8. Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:

|                                                                      |   | Year ended December 31, |        2024 |   |   |     |       2023 |   |
|:---------------------------------------------------------------------|:--|:------------------------|------------:|:--|:--|:----|-----------:|:--|
| Net loss attributable to shareholders                                | $ |                         | (11,155,516 | ) | $ |     | (5,314,765 | ) |
| Weighted average number of common shares outstanding during the year |   |                         |   9,619,184 |   |   |     |  3,479,494 |   |
| Basic and diluted net loss per share attributable to shareholders    | $ |                         |       (1.16 | ) | $ |     |      (1.53 | ) |

The Company’s potentially dilutive securities as of December 31, 2024 and 2023, include stock options, warrants, notes payable, convertible promissory notes and preferred shares. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the period ended December 31, 2024 and 2023 because